Biocon's Malaysia units received UK MHRA approval for its new drug product fill finish…

The record

Biocon's Malaysia units received UK MHRA approval for its new drug product fill finish unit for Semglee at its insulin manufacturing facility in Malaysia.

capitalmarket.com cnbctv18.com25 Sep 2026

Biocon's Malaysia units has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK for its new drug product fill finish unit for Semglee at its insulin manufacturing facility in Malaysia.

capitalmarket.com thehindubusinessline.com25 Sep 2026

Biocon

₹370.70

▲ +0.11%

Close (EOD), as of 1 Oct 2026 · source

Biocon: results, dividends, orders, the full cited record →

More on Biocon

Biocon Ltd gained for a third straight session on September 21, 2026.

21 Sep 2026 · 1 publisher

Biocon Biologics’ pertuzumab biosimilar has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

21 Sep 2026 · 1 publisher

Biocon has announced the signing of a partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil.

9 Sep 2026 · 1 publisher

Biocon has secured a 10-year supply contract for breast cancer drug pertuzumab with Bahiafarma and Bionovis in Brazil under the country’s Productive Development Partnership program.

9 Sep 2026 · 1 publisher

Biocon expects its biosimilars business to maintain double-digit revenue growth and targets mid-20% margins.

9 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.